ID   MKN45
AC   CVCL_0434
SY   MKN-45; MKN 45
DR   BTO; BTO:0001225
DR   CLO; CLO_0007733
DR   CLO; CLO_0050797
DR   EFO; EFO_0002832
DR   MCCL; MCC:0000329
DR   ArrayExpress; E-MTAB-783
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   BioGRID_ORCS_Cell_line; 404
DR   BioSample; SAMN03473237
DR   BioSample; SAMN03473585
DR   BioSample; SAMN10988555
DR   cancercelllines; CVCL_0434
DR   CCRID; 1101HUM-PUMC000229
DR   CCTCC; GDC0220
DR   Cell_Model_Passport; SIDM00247
DR   CGH-DB; 120-1
DR   CGH-DB; 9022-4
DR   ChEMBL-Cells; CHEMBL3307603
DR   ChEMBL-Targets; CHEMBL614354
DR   CLS; 300489
DR   Cosmic; 685596
DR   Cosmic; 801339
DR   Cosmic; 848147
DR   Cosmic; 848373
DR   Cosmic; 873711
DR   Cosmic; 877042
DR   Cosmic; 887256
DR   Cosmic; 888827
DR   Cosmic; 897535
DR   Cosmic; 918497
DR   Cosmic; 922696
DR   Cosmic; 925340
DR   Cosmic; 926114
DR   Cosmic; 968349
DR   Cosmic; 983727
DR   Cosmic; 1001651
DR   Cosmic; 1001655
DR   Cosmic; 1007602
DR   Cosmic; 1090461
DR   Cosmic; 1093299
DR   Cosmic; 1187283
DR   Cosmic; 1223589
DR   Cosmic; 1329185
DR   Cosmic; 1436026
DR   Cosmic; 1460707
DR   Cosmic; 1518241
DR   Cosmic; 1518255
DR   Cosmic; 1582430
DR   Cosmic; 1627265
DR   Cosmic; 1995510
DR   Cosmic; 2036663
DR   Cosmic; 2807633
DR   Cosmic; 2823225
DR   Cosmic-CLP; 925340
DR   DepMap; ACH-000356
DR   DSMZ; ACC-409
DR   DSMZCellDive; ACC-409
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001000978
DR   GDSC; 925340
DR   GEO; GSM552364
DR   GEO; GSM562395
DR   GEO; GSM618013
DR   GEO; GSM618014
DR   GEO; GSM618015
DR   GEO; GSM618016
DR   GEO; GSM827532
DR   GEO; GSM828836
DR   GEO; GSM844607
DR   GEO; GSM887324
DR   GEO; GSM888400
DR   GEO; GSM1374681
DR   GEO; GSM1670113
DR   IARC_TP53; 21633
DR   IARC_TP53; 30213
DR   IBRC; C10137
DR   JCRB; JCRB0254
DR   KCLB; 80103
DR   LiGeA; CCLE_725
DR   LINCS_LDP; LCL-1535
DR   NCBI_Iran; C615
DR   PharmacoDB; MKN45_938_2019
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0434
DR   PubChem_Cell_line; CVCL_0434
DR   RCB; RCB1001
DR   Wikidata; Q28473066
RX   CelloPub=CLPUB00581;
RX   CelloPub=CLPUB00584;
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RX   DOI=10.1016/j.procbio.2020.01.033;
RX   PubMed=758928;
RX   PubMed=1370612;
RX   PubMed=1486568;
RX   PubMed=1778766;
RX   PubMed=1846553;
RX   PubMed=1933850;
RX   PubMed=2061947;
RX   PubMed=2105279;
RX   PubMed=3962675;
RX   PubMed=3986962;
RX   PubMed=6862145;
RX   PubMed=9023415;
RX   PubMed=9247707;
RX   PubMed=9290701;
RX   PubMed=9665481;
RX   PubMed=11107048;
RX   PubMed=11314020;
RX   PubMed=11668190;
RX   PubMed=15723654;
RX   PubMed=15767549;
RX   PubMed=15900046;
RX   PubMed=15901131;
RX   PubMed=18804159;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=22336246;
RX   PubMed=22460905;
RX   PubMed=22531121;
RX   PubMed=23671654;
RX   PubMed=24587255;
RX   PubMed=24807215;
RX   PubMed=25343454;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25960936;
RX   PubMed=26589293;
RX   PubMed=27397505;
RX   PubMed=28196595;
RX   PubMed=29435981;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31978347;
RX   PubMed=35839778;
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/m/cell-lines-detail-496.html
WW   https://tcpaportal.org/mclp/
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: JFCR45 cancer cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Population: Japanese.
CC   Characteristics: MET-amplified, contains 12-13 copies of the gene (PubMed=29435981).
CC   Doubling time: 30-33 hours (PubMed=3962675); 33 hours (PubMed=29435981); 30-38 hours (CelloPub=CLPUB00584); 16 hours (PubMed=2105279); ~60 hours (DSMZ=ACC-409).
CC   HLA typing: A*24:02,24:02; B*52:01; C*12:02,12:02 (PubMed=25960936).
CC   HLA typing: A*24:02,24:02; B*52:01,67:02; C*12:02,12:02 (PubMed=26589293).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654; Sanger).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (Cosmic-CLP=925340; DepMap=ACH-000356).
CC   Omics: Array-based CGH.
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Genome ancestry: African=1.54%; Native American=0%; East Asian, North=85.37%; East Asian, South=9.42%; South Asian=0%; European, North=0%; European, South=3.67% (PubMed=30894373).
CC   Caution: Was indicated not to have a TP53 mutation in PubMed=1370612 and PubMed=15900046.
CC   Misspelling: MKN46; Cosmic=968349.
CC   Misspelling: MNK-45; Note=Occasionally.
CC   Misspelling: MNK45; Note=Occasionally.
CC   Misspelling: NKM-45; Note=Occasionally.
CC   Misspelling: NKM45; Note=Occasionally.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
ST   Source(s): CCRID=1101HUM-PUMC000229; CLS=300489; Cosmic-CLP=925340; DSMZ=ACC-409; JCRB=JCRB0254; KCLB=80103; PubMed=25877200; RCB=RCB1001
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D12S391: 26
ST   D13S317: 8,11
ST   D16S539: 10
ST   D18S51: 16
ST   D19S433: 14,16.2 (CCRID=1101HUM-PUMC000229; CLS=300489)
ST   D19S433: 14,17 (DSMZ=ACC-409)
ST   D21S11: 31
ST   D2S1338: 18
ST   D3S1358: 15,16
ST   D5S818: 10,11
ST   D6S1043: 14
ST   D7S820: 10,11
ST   D8S1179: 13,17
ST   FGA: 19 (KCLB=80103)
ST   FGA: 19,24 (CCRID=1101HUM-PUMC000229; CLS=300489; DSMZ=ACC-409; PubMed=25877200)
ST   Penta D: 10
ST   Penta E: 10
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 19
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-09-24; Version: 47
//
RX   CelloPub=CLPUB00581;
RA   Hojo H.;
RT   "Establishment of cultured cell lines of human stomach cancer origin
RT   and their morphological characteristics.";
RL   Niigata Igakkai Zasshi 91:737-763(1977).
//
RX   CelloPub=CLPUB00584;
RA   Motoyama T., Hojo H., Suzuki T., Oboshi S.;
RT   "Evaluation of the regrowth assay method as an in vitro drug sensitivity
RT   test and its application to cultured human gastric cancer cell lines.";
RL   Acta Med. Biol. 27:49-63(1979).
//
RX   DOI=10.1016/B978-0-12-333530-2.50014-9;
RA   Sekiguchi M., Suzuki T.;
RT   "Gastric tumor cell lines.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.287-316; Academic Press; New York; USA (1994).
//
RX   DOI=10.1016/j.procbio.2020.01.033;
RA   Pouremamali F., Jeddi F., Samadi N.;
RT   "Nrf2-ME-1 axis is associated with 5-FU resistance in gastric cancer
RT   cell line.";
RL   Process Biochem. 114:174-184(2022).
//
RX   PubMed=758928; DOI=10.1038/bjc.1979.3; PMCID=PMC2009802;
RA   Kinjo M., Oka K., Naito S., Kohga S., Tanaka K., Oboshi S., Hayata Y.,
RA   Yasumoto K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human cancer
RT   cell lines.";
RL   Br. J. Cancer 39:15-23(1979).
//
RX   PubMed=1370612; DOI=10.1016/S0006-291X(05)80133-0;
RA   Matozaki T., Sakamoto C., Matsuda K., Suzuki T., Konda Y., Nakano O.,
RA   Wada K., Uchida T., Nishisaki H., Nagao M., Kasuga M.;
RT   "Missense mutations and a deletion of the p53 gene in human gastric
RT   cancer.";
RL   Biochem. Biophys. Res. Commun. 182:215-223(1992).
//
RX   PubMed=1486568; DOI=10.1016/0165-4608(92)90350-H;
RA   Rege-Cambrin G., Scaravaglio P., Carozzi F., Giordano S., Ponzetto C.,
RA   Comoglio P.M., Saglio G.;
RT   "Karyotypic analysis of gastric carcinoma cell lines carrying an
RT   amplified c-met oncogene.";
RL   Cancer Genet. Cytogenet. 64:170-173(1992).
//
RX   PubMed=1778766; DOI=10.1111/j.1349-7006.1991.tb01816.x; PMCID=PMC5918361;
RA   Takeshima E., Hamaguchi M., Watanabe T., Akiyama S., Kataoka M.,
RA   Ohnishi Y., Xiao H.-Y., Nagai Y., Takagi H.;
RT   "Aberrant elevation of tyrosine-specific phosphorylation in human
RT   gastric cancer cells.";
RL   Jpn. J. Cancer Res. 82:1428-1435(1991).
//
RX   PubMed=1846553; DOI=10.1038/bjc.1991.14; PMCID=PMC1971664;
RA   Durrant L.G., Watson S.A., Hall A., Morris D.L.;
RT   "Co-stimulation of gastrointestinal tumour cell growth by gastrin,
RT   transforming growth factor alpha and insulin like growth factor-I.";
RL   Br. J. Cancer 63:67-70(1991).
//
RX   PubMed=1933850;
RA   Yamada Y., Yoshida T., Hayashi K., Sekiya T., Yokota J., Hirohashi S.,
RA   Nakatani K., Nakano H., Sugimura T., Terada M.;
RT   "p53 gene mutations in gastric cancer metastases and in gastric cancer
RT   cell lines derived from metastases.";
RL   Cancer Res. 51:5800-5805(1991).
//
RX   PubMed=2061947; DOI=10.1093/jnci/83.12.866;
RA   Watson S.A., Durrant L.G., Wencyk P.M., Watson A.L., Morris D.L.;
RT   "Intracellular gastrin in human gastrointestinal tumor cells.";
RL   J. Natl. Cancer Inst. 83:866-871(1991).
//
RX   PubMed=2105279; DOI=10.1002/ijc.2910450117;
RA   Watson S.A., Durrant L.G., Morris D.L.;
RT   "The effect of the E2 prostaglandin enprostil, and the somatostatin
RT   analogue SMS 201 995, on the growth of a human gastric cell line,
RT   MKN45G.";
RL   Int. J. Cancer 45:90-94(1990).
//
RX   PubMed=3962675; DOI=10.1111/j.1440-1827.1986.tb01461.x;
RA   Motoyama T., Hojo H., Watanabe H.;
RT   "Comparison of seven cell lines derived from human gastric
RT   carcinomas.";
RL   Acta Pathol. Jpn. 36:65-83(1986).
//
RX   PubMed=3986962; DOI=10.1093/carcin/6.4.549;
RA   Watatani M., Ikenaga M., Hatanaka T., Kinuta M., Takai S.-i., Mori T.,
RA   Kondo S.;
RT   "Analysis of N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)-induced DNA
RT   damage in tumor cell strains from Japanese patients and demonstration
RT   of MNNG hypersensitivity of Mer xenografts in athymic nude mice.";
RL   Carcinogenesis 6:549-553(1985).
//
RX   PubMed=6862145; DOI=10.20772/cancersci1959.74.2_240;
RA   Naito S., Inoue S., Kinjo M., Tanaka K.;
RT   "Thromboplastic and fibrinolytic activities of cultured human gastric
RT   cancer cell lines.";
RL   Gann 74:240-247(1983).
//
RX   PubMed=9023415; DOI=10.1006/cimm.1996.1062;
RA   Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.;
RT   "HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating
RT   lymphocytes of patients with non-small cell lung cancer.";
RL   Cell. Immunol. 175:101-110(1997).
//
RX   PubMed=9247707; DOI=10.1080/15216549700202901;
RA   Hatakeyama S., Gao Y.-H., Ohara-Nemoto Y., Kataoka H., Satoh M.;
RT   "Expression of bone morphogenetic proteins of human neoplastic
RT   epithelial cells.";
RL   Biochem. Mol. Biol. Int. 42:497-505(1997).
//
RX   PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D;
RA   Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T.,
RA   Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M.,
RA   Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.;
RT   "Screening the p53 status of human cell lines using a yeast functional
RT   assay.";
RL   Mol. Carcinog. 19:243-253(1997).
//
RX   PubMed=9665481; DOI=10.1016/S0002-9440(10)65561-7; PMCID=PMC1852940;
RA   Paciucci R., Vila M.R., Adell T., Diaz V.M., Tora M., Nakamura T.,
RA   Real F.X.;
RT   "Activation of the urokinase plasminogen activator/urokinase
RT   plasminogen activator receptor system and redistribution of E-cadherin
RT   are associated with hepatocyte growth factor-induced motility of
RT   pancreas tumor cells overexpressing Met.";
RL   Am. J. Pathol. 153:201-212(1998).
//
RX   PubMed=11107048; DOI=10.1046/j.1440-1827.2000.01117.x;
RA   Yokozaki H.;
RT   "Molecular characteristics of eight gastric cancer cell lines
RT   established in Japan.";
RL   Pathol. Int. 50:767-777(2000).
//
RX   PubMed=11314020; DOI=10.1038/sj.onc.1204160;
RA   Kataoka H., Miura Y., Joh T., Seno K., Tada T., Tamaoki T.,
RA   Nakabayashi H., Kawaguchi M., Asai K., Kato T., Itoh M.;
RT   "Alpha-fetoprotein producing gastric cancer lacks transcription factor
RT   ATBF1.";
RL   Oncogene 20:869-873(2001).
//
RX   PubMed=11668190; DOI=10.1177/002215540104901105;
RA   Quentmeier H., Osborn M., Reinhardt J., Zaborski M., Drexler H.G.;
RT   "Immunocytochemical analysis of cell lines derived from solid
RT   tumors.";
RL   J. Histochem. Cytochem. 49:1369-1378(2001).
//
RX   PubMed=15723654; DOI=10.1111/j.1349-7006.2005.00016.x; PMCID=PMC11160020;
RA   Takada H., Imoto I., Tsuda H., Sonoda I., Ichikura T., Mochizuki H.,
RA   Okanoue T., Inazawa J.;
RT   "Screening of DNA copy-number aberrations in gastric cancer cell lines
RT   by array-based comparative genomic hybridization.";
RL   Cancer Sci. 96:100-110(2005).
//
RX   PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234;
RA   Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y.,
RA   Yamori T.;
RT   "Chemosensitivity profile of cancer cell lines and identification of
RT   genes determining chemosensitivity by an integrated bioinformatical
RT   approach using cDNA arrays.";
RL   Mol. Cancer Ther. 4:399-412(2005).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=15901131; DOI=10.1016/j.prp.2005.01.002;
RA   Murai Y., Hayashi S., Takahashi H., Tsuneyama K., Takano Y.;
RT   "Correlation between DNA alterations and p53 and p16 protein
RT   expression in cancer cell lines.";
RL   Pathol. Res. Pract. 201:109-115(2005).
//
RX   PubMed=18804159; DOI=10.1016/j.ygeno.2008.08.002;
RA   Jung J.-J., Jeung H.-C., Chung H.C., Lee J.O., Kim T.S., Kim Y.T.,
RA   Noh S.H., Rha S.Y.;
RT   "In vitro pharmacogenomic database and chemosensitivity predictive
RT   genes in gastric cancer.";
RL   Genomics 93:52-61(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113;
RA   Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D.-X., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22531121; DOI=10.2739/kurumemedj.58.73;
RA   Koga A., Aoyagi K., Imaizumi T., Miyagi M., Shirouzu K.;
RT   "Comparison between the gastric cancer cell line MKN-45 and the
RT   high-potential peritoneal dissemination gastric cancer cell line
RT   MKN-45P.";
RL   Kurume Med. J. 58:73-79(2011).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056; PMCID=PMC3646030;
RA   Lu Y.-H., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=24587255; DOI=10.1371/journal.pone.0090155; PMCID=PMC3937424;
RA   Endo F., Nishizuka S.S., Kume K., Ishida K., Katagiri H., Ishida K.,
RA   Sato K., Iwaya T., Koeda K., Wakabayashi G.;
RT   "A compensatory role of NF-kappaB to p53 in response to 5-FU-based
RT   chemotherapy for gastric cancer cell lines.";
RL   PLoS ONE 9:E90155-E90155(2014).
//
RX   PubMed=24807215; DOI=10.1038/ncomms4830; PMCID=PMC4024760;
RA   Liu J.-F., McCleland M.L., Stawiski E.W., Gnad F., Mayba O., Haverty P.M.,
RA   Durinck S., Chen Y.-J., Klijn C., Jhunjhunwala S., Lawrence M.,
RA   Liu H.-B., Wan Y.-N., Chopra V.S., Yaylaoglu M.B., Yuan W.-L., Ha C.,
RA   Gilbert H.N., Reeder J., Pau G., Stinson J., Stern H.M., Manning G.,
RA   Wu T.D., Neve R.M., de Sauvage F.J., Modrusan Z., Seshagiri S.,
RA   Firestein R., Zhang Z.-M.;
RT   "Integrated exome and transcriptome sequencing reveals ZAK isoform
RT   usage in gastric cancer.";
RL   Nat. Commun. 5:3830.1-3830.8(2014).
//
RX   PubMed=25343454; DOI=10.1371/journal.pone.0111146; PMCID=PMC4208810;
RA   Choong M.-L., Tan S.-H., Tan T.-Z., Manesh S., Ngo A., Yong J.W.-Y.,
RA   Yang H.H., Lee M.A.;
RT   "Molecular integrative clustering of Asian gastric cell lines revealed
RT   two distinct chemosensitivity clusters.";
RL   PLoS ONE 9:E111146-E111146(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:e954893.1-e954893.12(2014).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076;
RA   Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P.,
RA   Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=29435981; DOI=10.1002/ijc.31304;
RA   Kim H.J., Kang S.K., Kwon W.S., Kim T.S., Jeong I., Jeung H.-C.,
RA   Kragh M., Horak I.D., Chung H.C., Rha S.Y.;
RT   "Forty-nine gastric cancer cell lines with integrative genomic
RT   profiling for development of c-MET inhibitor.";
RL   Int. J. Cancer 143:151-159(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//